Replies to post #9178 on GTC Biotherapeutics (fka GTCB)

[biopearl]

Please answer soon, I am running out of "Depends" and I need to know if I should buy another box. bp

[DewDiligence]

Re: Merrimack

>The take away is #1. Not enough side effects to stop the study #2. Enough efficacy that patients are willing to continue in the open label arm. #3. Continued demand for product from our goats.<

The appeal of MM-093 relative to other biologics for RA has always been its excellent tolerability. If the efficacy is there, MM-093 ought to be a serious player, at least in the second-line setting.